This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

VIVO Cannabis Valuation

Is 23Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 23Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 23Q's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 23Q's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 23Q?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 23Q. This is calculated by dividing 23Q's market cap by their current preferred multiple.
What is 23Q's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CA$9.27m

23Q key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	-1.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 23Q's PS Ratio compare to its peers?

The above table shows the PS ratio for 23Q vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.2x
SBX SynBiotic	7.8x	50.2%	€30.4m
B8FK Biofrontera	0.5x	n/a	€13.8m
APPH Apontis Pharma	1.4x	17.8%	€56.6m
93M1 MPH Health Care	3.2x	6.0%	€109.6m
23Q VIVO Cannabis	0.4x	n/a	€9.3m

Price-To-Sales vs Peers: 23Q is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (2.8x).

Price to Earnings Ratio vs Industry

How does 23Q's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.3%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.3%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: 23Q is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Pharmaceuticals industry average (4x)

Price to Sales Ratio vs Fair Ratio

What is 23Q's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

23Q PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 23Q's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.